{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:28:15Z","timestamp":1790785695783,"version":"4.1.0"},"reference-count":163,"publisher":"Oxford University Press (OUP)","issue":"Supplement_9","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"European Union Next-GenerationEU NRRP\u2014Research Projects of National Interest"},{"DOI":"10.13039\/501100003407","name":"Italian Ministry for University and Research","doi-asserted-by":"crossref","award":["2022Z4KJ48"],"award-info":[{"award-number":["2022Z4KJ48"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Radiopharmaceutical theranostic treatments have grown exponentially worldwide, and internal dosimetry has attracted attention and resources. Despite some similarities with chemotherapy, radiopharmaceutical treatments are essentially radiotherapy treatments, as the release of radiation into tissues is the determinant of the observed clinical effects. Therefore, absorbed dose calculations are key to explaining dose-effect correlations and individualizing radiopharmaceutical treatments. The present article introduces the basic principles of internal dosimetry and provides an overview of available loco-regional and systemic radiopharmaceutical treatments for central nervous system (CNS) tumors. The specific characteristics of dosimetry as applied to these treatments are highlighted, along with their limitations and most relevant results. Dosimetry is performed with higher precision and better reproducibility than in the past, and dosimetric data should be systematically collected, as treatment planning and verification may help exploit the full potential of theranostic of CNS tumors.<\/jats:p>","DOI":"10.1093\/neuonc\/noae200","type":"journal-article","created":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T23:22:09Z","timestamp":1727220129000},"page":"S242-S258","source":"Crossref","is-referenced-by-count":7,"title":["Do we need dosimetry for the optimization of theranostics in CNS tumors?"],"prefix":"10.1093","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4664-1965","authenticated-orcid":false,"given":"Francesco","family":"Cicone","sequence":"first","affiliation":[{"name":"Nuclear Medicine Unit, Department of Experimental and Clinical Medicine, \u201cMagna Graecia\u201d University of Catanzaro , Catanzaro ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvano","family":"Gnesin","sequence":"additional","affiliation":[{"name":"Institute of Radiation Physics, Lausanne University Hospital and University of Lausanne , Lausanne ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Santo","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Unit, Department of Experimental and Clinical Medicine, \u201cMagna Graecia\u201d University of Catanzaro , Catanzaro ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Stokke","sequence":"additional","affiliation":[{"name":"Department of Physics, University of Oslo , Oslo ,","place":["Norway"]},{"name":"Department of Diagnostic Physics and Computational Radiology, Division of Radiology and Nuclear Medicine, Oslo University Hospital , Oslo ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirco","family":"Bartolomei","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Unit, Department of Oncology and Haematology, Azienda Ospedaliero-Universitaria di Ferrara , Ferrara ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe Lucio","family":"Cascini","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Unit, Department of Experimental and Clinical Medicine, \u201cMagna Graecia\u201d University of Catanzaro , Catanzaro ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Minniti","sequence":"additional","affiliation":[{"name":"IRCCS Neuromed , Pozzilli (IS) ,","place":["Italy"]},{"name":"Radiation Oncology Unit, Department of Radiological Sciences, Oncology and Anatomical Pathology, \u201cSapienza\u201d University of Rome , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Paganelli","sequence":"additional","affiliation":[{"name":"IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori,\u201d Meldola ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Verger","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Nancyclotep Imaging Platform, CHRU-Nancy, IADI, INSERM, UMR 1254, Universit\u00e9 de Lorraine , Nancy ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Cremonesi","sequence":"additional","affiliation":[{"name":"Unit of Radiation Research, IEO, European Institute of Oncology IRCCS , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,10,1]]},"reference":[{"issue":"3","key":"2024121023463368800_CIT0001","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1152\/ajplegacy.1940.128.3.565","article-title":"Radioactive iodine as an indicator in thyroid physiology","volume":"128","author":"Hertz","year":"1940","journal-title":"Am J Physiol-Legacy Content"},{"issue":"2","key":"2024121023463368800_CIT0002","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med."},{"issue":"12","key":"2024121023463368800_CIT0003","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med."},{"issue":"EFOMP PS19","key":"2024121023463368800_CIT0004","doi-asserted-by":"crossref","first-page":"103188","DOI":"10.1016\/j.ejmp.2023.103188","article-title":"The contest between internal and external-beam dosimetry: The Zeno\u2019s paradox of Achilles and the tortoise","volume":"117","author":"Cicone","year":"2024","journal-title":"Phys Med."},{"issue":"11","key":"2024121023463368800_CIT0005","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1007\/s00259-017-3707-3","article-title":"The conflict between treatment optimization and registration of radiopharmaceuticals with fixed activity posology in oncological nuclear medicine therapy","volume":"44","author":"Chiesa","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"1126","key":"2024121023463368800_CIT0006","doi-asserted-by":"crossref","first-page":"20210547","DOI":"10.1259\/bjr.20210547","article-title":"The internal dosimetry user group position statement on molecular radiotherapy","volume":"94","author":"Gear","year":"2021","journal-title":"Br J Radiol."},{"key":"2024121023463368800_CIT0007"},{"issue":"1","key":"2024121023463368800_CIT0008","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s40658-017-0194-3","article-title":"Dosimetry-based treatment planning for molecular radiotherapy: A summary of the 2017 report from the Internal Dosimetry Task Force","volume":"4","author":"Stokke","year":"2017","journal-title":"EJNMMI Phys"},{"issue":"13","key":"2024121023463368800_CIT0009","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1007\/s00259-018-4136-7","article-title":"EANM practical guidance on uncertainty analysis for molecular radiotherapy absorbed dose calculations","volume":"45","author":"Gear","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2024121023463368800_CIT0010","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ejmp.2021.11.001","article-title":"Overview of commercial treatment planning systems for targeted radionuclide therapy","volume":"92","author":"Della Gala","year":"2021","journal-title":"Phys Med."},{"issue":"1","key":"2024121023463368800_CIT0011","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s40658-021-00397-0","article-title":"A multicentre and multi-national evaluation of the accuracy of quantitative Lu-177 SPECT\/CT imaging performed within the MRTDosimetry project","volume":"8","author":"Tran-Gia","year":"2021","journal-title":"EJNMMI Phys"},{"key":"2024121023463368800_CIT0012","doi-asserted-by":"crossref","first-page":"36S","DOI":"10.2967\/jnumed.121.262748","article-title":"An International Study of Factors Affecting Variability of Dosimetry Calculations, Part 1: Design and early results of the SNMMI dosimetry challenge","volume":"62","author":"Uribe","year":"2021","journal-title":"J Nucl Med."},{"issue":"11","key":"2024121023463368800_CIT0013","first-page":"1665","article-title":"A Pipeline for automated voxel dosimetry: Application in patients with multi-SPECT\/CT Imaging After 177Lu-Peptide receptor radionuclide therapy","volume":"63","author":"Dewaraja","year":"2022","journal-title":"J Nucl Med."},{"issue":"6","key":"2024121023463368800_CIT0014","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1007\/s00259-022-05727-7","article-title":"EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands","volume":"49","author":"Sj\u00f6green Gleisner","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"7","key":"2024121023463368800_CIT0015","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1007\/s00259-023-06226-z","article-title":"EANM enabling guide: How to improve the accessibility of clinical dosimetry [published correction appears in Eur J Nucl Med Mol Imaging. 2023 Aug;50(10):3157-3158.]","volume":"50","author":"Gear","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"9","key":"2024121023463368800_CIT0016","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1007\/s00259-023-06215-2","article-title":"Results from an EANM survey on time estimates and personnel responsible for main tasks in molecular radiotherapy dosimetry","volume":"50","author":"Gabi\u00f1a","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2024121023463368800_CIT0017","doi-asserted-by":"crossref","first-page":"103192","DOI":"10.1016\/j.ejmp.2023.103192","article-title":"Time-Activity data fitting in molecular Radiotherapy: Methodology and pitfalls","volume":"117","author":"Ivashchenko","year":"2024","journal-title":"Phys Med."},{"issue":"11","key":"2024121023463368800_CIT0018","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1007\/s00259-015-3068-8","article-title":"Radioembolization of hepatocarcinoma with (90)Y glass microspheres: Development of an individualized treatment planning strategy based on dosimetry and radiobiology","volume":"42","author":"Chiesa","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"6","key":"2024121023463368800_CIT0019","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1007\/s00259-018-3945-z","article-title":"Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): Feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity","volume":"45","author":"Garske-Rom\u00e1n","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"3","key":"2024121023463368800_CIT0020","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1007\/s00259-018-4209-7","article-title":"Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: Initial results from the P-PRRT trial","volume":"46","author":"Del Prete","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"11","key":"2024121023463368800_CIT0021","doi-asserted-by":"crossref","first-page":"3830","DOI":"10.1007\/s00259-022-05786-w","article-title":"Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based 177Lu-DOTATATE treatment of NET patients","volume":"49","author":"Sundl\u00f6v","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"1","key":"2024121023463368800_CIT0022","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2468-1253(20)30290-9","article-title":"Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): A randomised, multicentre, open-label phase 2 trial","volume":"6","author":"Garin","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"2024121023463368800_CIT0023","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1053\/j.semnuclmed.2021.11.001","article-title":"Dosimetric approaches for radioimmunotherapy of non-hodgkin lymphoma in myeloablative setting","volume":"52","author":"Cicone","year":"2022","journal-title":"Semin Nucl Med."},{"issue":"5","key":"2024121023463368800_CIT0024","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1007\/s00259-020-05163-5","article-title":"International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres","volume":"48","author":"Levillain","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"2","key":"2024121023463368800_CIT0025","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s00259-022-05956-w","article-title":"Clinical, dosimetric, and reporting considerations for Y-90 glass microspheres in hepatocellular carcinoma: Updated 2022 recommendations from an international multidisciplinary working group","volume":"50","author":"Salem","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"2","key":"2024121023463368800_CIT0026","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2967\/jnumed.123.266205","article-title":"Theranostics in neurooncology: Heading toward new horizons","volume":"65","author":"Tolboom","year":"2024","journal-title":"J Nucl Med."},{"issue":"9","key":"2024121023463368800_CIT0027","doi-asserted-by":"crossref","first-page":"e441","DOI":"10.1016\/S1470-2045(24)00145-1","article-title":"Translating the theranostic concept to neuro-oncology: Disrupting barriers","volume":"25","author":"Albert","year":"2024","journal-title":"Lancet Oncol."},{"key":"2024121023463368800_CIT0028","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/B978-0-12-822960-6.00142-3","article-title":"Fundamentals of internal radiation dosimetry","volume-title":"Nuclear medicine and molecular imaging","author":"Amato","year":"2022"},{"key":"2024121023463368800_CIT0029","volume-title":"Dosimetry for Radiopharmaceutical Therapy (Principles of Dosimetry in Radiopharmaceutical Therapies). Non-serial Publications","author":"Dewaraja","year":"2024"},{"issue":"3","key":"2024121023463368800_CIT0030","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2967\/jnumed.108.056036","article-title":"MIRD pamphlet No. 21: A generalized schema for radiopharmaceutical dosimetry--standardization of nomenclature","volume":"50","author":"Bolch","year":"2009","journal-title":"J Nucl Med."},{"issue":"18","key":"2024121023463368800_CIT0031","doi-asserted-by":"crossref","first-page":"7804","DOI":"10.7150\/thno.77279","article-title":"Current use and future potential of (physiologically based) pharmacokinetic modelling of radiopharmaceuticals: A review","volume":"12","author":"Siebinga","year":"2022","journal-title":"Theranostics"},{"issue":"6","key":"2024121023463368800_CIT0032","first-page":"1023","article-title":"OLINDA\/EXM: The second-generation personal computer software for internal dose assessment in nuclear medicine","volume":"46","author":"Stabin","year":"2005","journal-title":"J Nucl Med."},{"issue":"7","key":"2024121023463368800_CIT0033","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.2967\/jnumed.122.264225","article-title":"MIRD Pamphlet No. 28, Part 1: MIRDcalc-a software tool for medical internal radiation dosimetry","volume":"64","author":"Kesner","year":"2023","journal-title":"J Nucl Med."},{"issue":"1","key":"2024121023463368800_CIT0034","first-page":"11S","article-title":"MIRD pamphlet No. 17: The dosimetry of nonuniform activity distributions--radionuclide S values at the voxel level. Medical Internal Radiation Dose Committee","volume":"40","author":"Bolch","year":"1999","journal-title":"J Nucl Med."},{"key":"2024121023463368800_CIT0035","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ejmp.2018.05.005","article-title":"A Monte Carlo model for the internal dosimetry of choroid plexuses in nuclear medicine procedures","volume":"49","author":"Amato","year":"2018","journal-title":"Phys Med."},{"key":"2024121023463368800_CIT0036","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.nima.2013.01.014","article-title":"Use of the GEANT4 Monte Carlo to determine three-dimensional dose factors for radionuclide dosimetry","volume":"708","author":"Amato","year":"2013","journal-title":"Nucl Instrum Methods Phys Res Sect A."},{"issue":"Suppl 3","key":"2024121023463368800_CIT0037","doi-asserted-by":"crossref","first-page":"23S","DOI":"10.2967\/jnumed.121.262751","article-title":"Normal-tissue tolerance to radiopharmaceutical therapies, the knowns and the unknowns","volume":"62","author":"Wahl","year":"2021","journal-title":"J Nucl Med."},{"issue":"4","key":"2024121023463368800_CIT0038","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00411-022-01000-5","article-title":"Heterogeneity of dose distribution in normal tissues in case of radiopharmaceutical therapy with alpha-emitting radionuclides","volume":"61","author":"Li","year":"2022","journal-title":"Radiat Environ Biophys."},{"issue":"1","key":"2024121023463368800_CIT0039","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1118\/1.598063","article-title":"Reporting and analyzing dose distributions: A concept of equivalent uniform dose","volume":"24","author":"Niemierko","year":"1997","journal-title":"Med Phys."},{"issue":"2","key":"2024121023463368800_CIT0040","first-page":"71","article-title":"The role of biologically effective dose (BED) in clinical oncology","volume":"13","author":"Jones","year":"2001","journal-title":"Clin Oncol (R Coll Radiol)."},{"issue":"1","key":"2024121023463368800_CIT0041","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13014-018-1040-z","article-title":"The alfa and beta of tumours: A review of parameters of the linear-quadratic model, derived from clinical radiotherapy studies","volume":"13","author":"van Leeuwen","year":"2018","journal-title":"Radiat Oncol."},{"issue":"1093","key":"2024121023463368800_CIT0042","doi-asserted-by":"crossref","first-page":"20180070","DOI":"10.1259\/bjr.20180070","article-title":"Radiation repair models for clinical application","volume":"92","author":"Dale","year":"2019","journal-title":"Br J Radiol."},{"issue":"11","key":"2024121023463368800_CIT0043","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.2967\/jnumed.108.053173","article-title":"MIRD pamphlet No. 20: The effect of model assumptions on kidney dosimetry and response--implications for radionuclide therapy [published correction appears in J Nucl Med. 2011 Sep;52(9):1498]","volume":"49","author":"Wessels","year":"2008","journal-title":"J Nucl Med."},{"issue":"15","key":"2024121023463368800_CIT0044","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1200\/JCO.23.01241","article-title":"How can radiopharmaceutical therapies reach their full potential? Improving dose reporting and Phase I Clinical Trial Design","volume":"42","author":"Kiess","year":"2024","journal-title":"J Clin Oncol."},{"issue":"6","key":"2024121023463368800_CIT0045","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s00701-019-03882-9","article-title":"Intracavitary radioimmunotherapy of high-grade gliomas: Present status and future developments","volume":"161","author":"Reulen","year":"2019","journal-title":"Acta Neurochir (Wien)."},{"issue":"1","key":"2024121023463368800_CIT0046","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/ijc.2910510103","article-title":"Treatment of intracranial human glioblastoma by direct intratumoral administration of 131I-labelled anti-tenascin monoclonal antibody BC-2","volume":"51","author":"Riva","year":"1992","journal-title":"Int J Cancer."},{"key":"2024121023463368800_CIT0047","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/BF02789213","article-title":"Glioblastoma therapy by direct intralesional administration of I-131 radioiodine labeled antitenascin antibodies","volume":"24-25","author":"Riva","year":"1994","journal-title":"Cell Biophys"},{"issue":"3-4","key":"2024121023463368800_CIT0048","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/BF02187762","article-title":"Intralesional administration of I-131 labelled monoclonal antibodies in the treatment of malignant gliomas","volume":"135","author":"Arista","year":"1995","journal-title":"Acta Neurochir (Wien)."},{"issue":"3","key":"2024121023463368800_CIT0049","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1080\/028418699431438","article-title":"131I radioconjugated antibodies for the locoregional radioimmunotherapy of high-grade malignant glioma--phase I and II study","volume":"38","author":"Riva","year":"1999","journal-title":"Acta Oncol."},{"issue":"11","key":"2024121023463368800_CIT0050","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1002\/cncr.11796","article-title":"Expression of tenascin-C in various human brain tumors and its relevance for survival in patients with astrocytoma","volume":"98","author":"Leins","year":"2003","journal-title":"Cancer."},{"issue":"22","key":"2024121023463368800_CIT0051","doi-asserted-by":"crossref","first-page":"3862","DOI":"10.1200\/JCO.2000.18.22.3862","article-title":"Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas","volume":"18","author":"Cokgor","year":"2000","journal-title":"J Clin Oncol."},{"issue":"5","key":"2024121023463368800_CIT0052","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1200\/JCO.2002.20.5.1389","article-title":"Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas","volume":"20","author":"Reardon","year":"2002","journal-title":"J Clin Oncol."},{"issue":"6","key":"2024121023463368800_CIT0053","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1200\/JCO.1998.16.6.2202","article-title":"Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results","volume":"16","author":"Bigner","year":"1998","journal-title":"J Clin Oncol."},{"issue":"1","key":"2024121023463368800_CIT0054","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1200\/JCO.2005.03.4082","article-title":"Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: Phase II study results [published correction appears in J Clin Oncol. 2006 Mar 20;24(9):1484]","volume":"24","author":"Reardon","year":"2006","journal-title":"J Clin Oncol."},{"issue":"2","key":"2024121023463368800_CIT0055","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1215\/15228517-2007-053","article-title":"A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost","volume":"10","author":"Reardon","year":"2008","journal-title":"Neuro Oncol"},{"key":"2024121023463368800_CIT0056","first-page":"3275s","article-title":"Loco-regional radioimmunotherapy of high-grade malignant gliomas using specific monoclonal antibodies labeled with 90Y: A phase I study","volume":"5","author":"Riva","year":"1999","journal-title":"Clin Cancer Res."},{"issue":"3","key":"2024121023463368800_CIT0057","first-page":"227","article-title":"Pre-targeted locoregional radioimmunotherapy with 90Y-biotin in glioma patients: phase I study and preliminary therapeutic results","volume":"16","author":"Paganelli","year":"2001","journal-title":"Cancer Biother Radiopharm."},{"issue":"3","key":"2024121023463368800_CIT0058","first-page":"220","article-title":"Combined treatment of glioblastoma patients with locoregional pre-targeted 90Y-biotin radioimmunotherapy and temozolomide","volume":"48","author":"Bartolomei","year":"2004","journal-title":"Q J Nucl Med Mol Imaging."},{"issue":"2","key":"2024121023463368800_CIT0059","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11060-004-1497-5","article-title":"Intratumoral delivery of mitoxantrone in association with 90-Y radioimmunotherapy (RIT) in recurrent glioblastoma","volume":"72","author":"Boiardi","year":"2005","journal-title":"J Neurooncol."},{"issue":"2","key":"2024121023463368800_CIT0060","first-page":"337","article-title":"Coincidence of EGF receptors and somatostatin receptors in meningiomas but inverse, differentiation-dependent relationship in glial tumors","volume":"134","author":"Reubi","year":"1989","journal-title":"Am J Pathol."},{"issue":"5","key":"2024121023463368800_CIT0061","first-page":"1025","article-title":"Locoregional regulatory peptide receptor targeting with the diffusible somatostatin analogue 90Y-labeled DOTA0-D-Phe1-Tyr3-octreotide (DOTATOC): A pilot study in human gliomas","volume":"5","author":"Merlo","year":"1999","journal-title":"Clin Cancer Res."},{"issue":"43-44","key":"2024121023463368800_CIT0062","first-page":"640","article-title":"Successful diffusible brachytherapy (dBT) of a progressive low-grade astrocytoma using the locally injected peptidic vector and somatostatin analogue [90Y]-DOTA0-D-Phe1-Tyr3-octreotide (DOTATOC)","volume":"131","author":"Hofer","year":"2001","journal-title":"Swiss Med Wkly."},{"issue":"4","key":"2024121023463368800_CIT0063","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s00259-001-0717-x","article-title":"Local injection of the 90Y-labelled peptidic vector DOTATOC to control gliomas of WHO grades II and III: An extended pilot study","volume":"29","author":"Schumacher","year":"2002","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"3","key":"2024121023463368800_CIT0064","doi-asserted-by":"crossref","first-page":"397","DOI":"10.2967\/jnumed.109.072819","article-title":"Response of recurrent high-grade glioma to treatment with (90)Y-DOTATOC","volume":"51","author":"Heute","year":"2010","journal-title":"J Nucl Med."},{"issue":"6","key":"2024121023463368800_CIT0065","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1002\/ijc.2910610608","article-title":"Substance-P receptors in human primary neoplasms: Tumoral and vascular localization","volume":"61","author":"Hennig","year":"1995","journal-title":"Int J Cancer."},{"issue":"12","key":"2024121023463368800_CIT0066","doi-asserted-by":"crossref","first-page":"3843","DOI":"10.1158\/1078-0432.CCR-05-2820","article-title":"Local targeting of malignant gliomas by the diffusible peptidic vector 1,4,7,10-tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic acid-substance p","volume":"12","author":"Kneifel","year":"2006","journal-title":"Clin Cancer Res."},{"issue":"7","key":"2024121023463368800_CIT0067","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s00259-010-1385-5","article-title":"Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]-substance P: a pilot trial","volume":"37","author":"Cordier","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"9","key":"2024121023463368800_CIT0068","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1007\/s00259-018-4015-2","article-title":"Prolonged survival in secondary glioblastoma following local injection of targeted alpha therapy with 213Bi-substance P analogue","volume":"45","author":"Krolicki","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"3","key":"2024121023463368800_CIT0069","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1007\/s00259-018-4225-7","article-title":"Safety and efficacy of targeted alpha therapy with 213Bi-DOTA-substance P in recurrent glioblastoma","volume":"46","author":"Kr\u00f3licki","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"11","key":"2024121023463368800_CIT0070","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1007\/s00259-021-05350-y","article-title":"Dose escalation study of targeted alpha therapy with [225Ac]Ac-DOTA-substance P in recurrence glioblastoma - safety and efficacy","volume":"48","author":"Kr\u00f3licki","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"5","key":"2024121023463368800_CIT0071","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/RLU.0000000000004608","article-title":"Locoregional Treatment of Glioblastoma With Targeted \u03b1 Therapy: [213Bi]Bi-DOTA-Substance P Versus [225Ac]Ac-DOTA-Substance P-Analysis of Influence Parameters","volume":"48","author":"Kr\u00f3licki","year":"2023","journal-title":"Clin Nucl Med."},{"issue":"1","key":"2024121023463368800_CIT0072","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2967\/jnumed.107.046938","article-title":"Clinical experience with alpha-particle emitting 211At: Treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6","volume":"49","author":"Zalutsky","year":"2008","journal-title":"J Nucl Med."},{"issue":"3","key":"2024121023463368800_CIT0073","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/0360-3016(94)00396-3","article-title":"Pharmacokinetics and dose estimates following intrathecal administration of 131I-monoclonal antibodies for the treatment of central nervous system malignancies","volume":"31","author":"Papanastassiou","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"34","key":"2024121023463368800_CIT0074","doi-asserted-by":"crossref","first-page":"5465","DOI":"10.1200\/JCO.2007.11.1807","article-title":"Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using intra-Ommaya 131-I-3F8","volume":"25","author":"Kramer","year":"2007","journal-title":"J Clin Oncol."},{"issue":"3","key":"2024121023463368800_CIT0075","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s11060-009-0038-7","article-title":"Compartmental intrathecal radioimmunotherapy: Results for treatment for metastatic CNS neuroblastoma","volume":"97","author":"Kramer","year":"2010","journal-title":"J Neurooncol."},{"issue":"2","key":"2024121023463368800_CIT0076","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s11060-015-1788-z","article-title":"Low incidence of radionecrosis in children treated with conventional radiation therapy and intrathecal radioimmunotherapy","volume":"123","author":"Kramer","year":"2015","journal-title":"J Neurooncol."},{"issue":"1","key":"2024121023463368800_CIT0077","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/pbc.26754","article-title":"A phase II study of radioimmunotherapy with intraventricular 131 I-3F8 for medulloblastoma","volume":"65","author":"Kramer","year":"2018","journal-title":"Pediatr Blood Cancer."},{"issue":"1","key":"2024121023463368800_CIT0078","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s13045-022-01383-4","article-title":"Phase 1 study of intraventricular 131I-omburtamab targeting B7H3 (CD276)-expressing CNS malignancies","volume":"15","author":"Kramer","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"12","key":"2024121023463368800_CIT0079","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.2967\/jnumed.118.219576","article-title":"Biodistribution and dosimetry of intraventricularly administered 124i-omburtamab in patients with metastatic leptomeningeal tumors [published correction appears in J Nucl Med. 2021 Mar;62(3):404.]","volume":"60","author":"Pandit-Taskar","year":"2019","journal-title":"J Nucl Med."},{"issue":"1","key":"2024121023463368800_CIT0080","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11060-022-04235-w","article-title":"Outcomes of intraventricular 131-I-omburtamab and external beam radiotherapy in patients with recurrent medulloblastoma and ependymoma","volume":"162","author":"Tringale","year":"2023","journal-title":"J Neurooncol."},{"issue":"1","key":"2024121023463368800_CIT0081","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/0360-3016(92)91009-C","article-title":"Malignant astrocytomas treated with iodine-125 labeled monoclonal antibody 425 against epidermal growth factor receptor: A phase II trial","volume":"22","author":"Brady","year":"1992","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"2","key":"2024121023463368800_CIT0082","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1089\/hyb.1995.14.111","article-title":"Epidermal growth factor receptor 425 monoclonal antibodies radiolabeled with iodine-125 in the adjuvant treatment of high-grade astrocytomas","volume":"14","author":"Snelling","year":"1995","journal-title":"Hybridoma."},{"issue":"6","key":"2024121023463368800_CIT0083","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/01.COC.0000041009.06780.E5","article-title":"Radioiodinated (I-125) monoclonal antibody 425 in the treatment of high grade glioma patients: Ten-year synopsis of a novel treatment","volume":"25","author":"Emrich","year":"2002","journal-title":"Am J Clin Oncol."},{"issue":"2","key":"2024121023463368800_CIT0084","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3171\/2010.2.JNS091211","article-title":"A Phase II study of anti-epidermal growth factor receptor radioimmunotherapy in the treatment of glioblastoma multiforme","volume":"113","author":"Li","year":"2010","journal-title":"J Neurosurg."},{"issue":"3","key":"2024121023463368800_CIT0085","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1089\/hyb.2006.25.125","article-title":"Use of monoclonal anti-EGFR antibody in the radioimmunotherapy of malignant gliomas in the context of EGFR expression in grade III and IV tumors","volume":"25","author":"Wygoda","year":"2006","journal-title":"Hybridoma (Larchmt)"},{"issue":"12","key":"2024121023463368800_CIT0086","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.2967\/jnumed.109.066548","article-title":"Efficacy of systemic radionuclide therapy with p-131I-iodo-L-phenylalanine combined with external beam photon irradiation in treating malignant gliomas","volume":"50","author":"Samnick","year":"2009","journal-title":"J Nucl Med."},{"issue":"1","key":"2024121023463368800_CIT0087","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3413\/Nukmed-0510-12-06","article-title":"Patients with recurrent glioblastoma multiforme. Initial experience with p-[(131)I]iodo-L-phenylalanine and external beam radiation therapy","volume":"52","author":"Verburg","year":"2013","journal-title":"Nuklearmedizin."},{"issue":"4","key":"2024121023463368800_CIT0088","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/s002590050397","article-title":"Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin","volume":"26","author":"Paganelli","year":"1999","journal-title":"Eur J Nucl Med."},{"issue":"2","key":"2024121023463368800_CIT0089","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/sj.bjc.6600047","article-title":"Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients: A pilot study","volume":"86","author":"Grana","year":"2002","journal-title":"Br J Cancer."},{"issue":"6","key":"2024121023463368800_CIT0090","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1007\/s00259-020-04715-z","article-title":"Tumor uptake in glioblastoma multiforme after IV injection of [177Lu]Lu-PSMA-617","volume":"47","author":"Kunikowska","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2024121023463368800_CIT0091","doi-asserted-by":"crossref","first-page":"980058","DOI":"10.3389\/fonc.2022.980058","article-title":"[68Ga]Ga-PSMA PET\/MRI, histological PSMA expression and preliminary experience with [177Lu]Lu-PSMA therapy in relapsing high-grade glioma","volume":"12","author":"Truckenmueller","year":"2022","journal-title":"Front Oncol."},{"issue":"6","key":"2024121023463368800_CIT0092","doi-asserted-by":"crossref","first-page":"892","DOI":"10.2967\/jnumed.122.264850","article-title":"[177Lu]Lu-PSMA therapy as an individual treatment approach for patients with high-grade glioma: Dosimetry results and critical statement","volume":"64","author":"Graef","year":"2023","journal-title":"J Nucl Med."},{"issue":"1-2","key":"2024121023463368800_CIT0093","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1023\/B:NEON.0000013498.19981.55","article-title":"Expression of somatostatin receptor mRNA in human meningiomas and their implication in in vitro antiproliferative activity","volume":"66","author":"Arena","year":"2004","journal-title":"J Neurooncol."},{"key":"2024121023463368800_CIT0094","doi-asserted-by":"crossref","first-page":"i44","DOI":"10.1093\/neuonc\/noy143","article-title":"Imaging and diagnostic advances for intracranial meningiomas","volume":"21","author":"Huang","year":"2019","journal-title":"Neuro Oncol"},{"issue":"12","key":"2024121023463368800_CIT0095","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1007\/s00259-024-06783-x","article-title":"Joint EANM\/EANO\/RANO\/SNMMI practice guideline\/procedure standards for diagnostics and therapy (theranostics) of meningiomas using radiolabeled somatostatin receptor ligands: Version 1.0","volume":"51","author":"Albert","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"6","key":"2024121023463368800_CIT0096","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/neuonc\/not330","article-title":"Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: A RANO review","volume":"16","author":"Kaley","year":"2014","journal-title":"Neuro Oncol"},{"issue":"10","key":"2024121023463368800_CIT0097","first-page":"1599","article-title":"Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma","volume":"47","author":"van Essen","year":"2006","journal-title":"J Nucl Med."},{"issue":"9","key":"2024121023463368800_CIT0098","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1007\/s00259-009-1115-z","article-title":"Peptide receptor radionuclide therapy with (90)Y-DOTATOC in recurrent meningioma","volume":"36","author":"Bartolomei","year":"2009","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"5","key":"2024121023463368800_CIT0099","first-page":"193","article-title":"Peptide receptor radionuclide therapy in patients with inoperable meningiomas: Our experience and review of the literature","volume":"29","author":"Minutoli","year":"2014","journal-title":"Cancer Biother Radiopharm."},{"issue":"2","key":"2024121023463368800_CIT0100","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2967\/jnumed.114.147256","article-title":"Somatostatin receptor-targeted radiopeptide therapy with 90Y-DOTATOC and 177Lu-DOTATOC in progressive meningioma: Long-term results of a phase II clinical trial","volume":"56","author":"Marincek","year":"2015","journal-title":"J Nucl Med."},{"issue":"11","key":"2024121023463368800_CIT0101","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.2967\/jnumed.115.155853","article-title":"90Y-DOTATOC as a therapeutic option for complex recurrent or progressive meningiomas","volume":"56","author":"Gerster-Gilli\u00e9ron","year":"2015","journal-title":"J Nucl Med."},{"issue":"4","key":"2024121023463368800_CIT0102","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2967\/jnumed.120.249607","article-title":"Somatostatin Receptor-targeted radiopeptide therapy in treatment-refractory meningioma: Individual patient data meta-analysis","volume":"62","author":"Mirian","year":"2021","journal-title":"J Nucl Med."},{"issue":"8","key":"2024121023463368800_CIT0103","doi-asserted-by":"crossref","first-page":"5550","DOI":"10.3390\/curroncol29080438","article-title":"Somatostatin receptor theranostics for refractory meningiomas","volume":"29","author":"Salgues","year":"2022","journal-title":"Curr Oncol"},{"issue":"2","key":"2024121023463368800_CIT0104","doi-asserted-by":"crossref","first-page":"160","DOI":"10.4103\/wjnm.wjnm_39_18","article-title":"Prevalence of hitherto unknown brain meningioma detected on 68Ga-DOTATATE positron-emission tomography\/computed tomography in patients with metastatic neuroendocrine tumor and exploring potential of 177Lu-DOTATATE peptide receptor radionuclide therapy as single-shot treatment approach targeting both tumors","volume":"18","author":"Parghane","year":"2019","journal-title":"World J Nucl Med"},{"issue":"5","key":"2024121023463368800_CIT0105","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1055\/a-1200-0989","article-title":"Response assessment of somatostatin receptor targeted radioligand therapies for progressive intracranial meningioma. Ansprechen auf Somatostatinrezeptor-Radioligandentherapie bei intrakraniellen Meningeomen","volume":"59","author":"M\u00fcther","year":"2020","journal-title":"Nuklearmedizin."},{"issue":"4","key":"2024121023463368800_CIT0106","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1007\/s00259-022-06044-9","article-title":"Efficacy and safety of peptide receptor radionuclide therapy with [177Lu]Lu-DOTA-TATE in 15 patients with progressive treatment-refractory meningioma","volume":"50","author":"Minczeles","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"3","key":"2024121023463368800_CIT0107","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s11060-024-04622-5","article-title":"Peptide radionuclide radiation therapy with Lutathera in multirecurrent nonanaplastic meningiomas: Antitumoral activity study by growth rate analysis","volume":"167","author":"Graillon","year":"2024","journal-title":"J Neurooncol."},{"issue":"4","key":"2024121023463368800_CIT0108","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1158\/1078-0432.CCR-23-2533","article-title":"Evaluation of the SSTR2-targeted radiopharmaceutical 177Lu-DOTATATE and SSTR2-specific 68Ga-DOTATATE PET as imaging biomarker in patients with intracranial meningioma","volume":"30","author":"Kurz","year":"2024","journal-title":"Clin Cancer Res."},{"issue":"12","key":"2024121023463368800_CIT0109","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1007\/s00259-002-0965-4","article-title":"New approaches in targeting intracerebral tumours with 90Y-labelled radiopeptides","volume":"29","author":"Buscombe","year":"2002","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"3","key":"2024121023463368800_CIT0110","doi-asserted-by":"crossref","first-page":"406","DOI":"10.2967\/jnumed.121.262491","article-title":"Intraarterial administration boosts 177Lu-HA-DOTATATE accumulation in salvage meningioma patients","volume":"63","author":"Vonken","year":"2022","journal-title":"J Nucl Med."},{"issue":"4","key":"2024121023463368800_CIT0111","doi-asserted-by":"crossref","first-page":"573","DOI":"10.2967\/jnumed.123.266817","article-title":"Radiolabeled somatostatin receptor antagonist versus agonist for peptide receptor radionuclide therapy in patients with therapy-resistant meningioma: PROMENADE Phase 0 Study","volume":"65","author":"Eigler","year":"2024","journal-title":"J Nucl Med."},{"issue":"5","key":"2024121023463368800_CIT0112","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1007\/s00259-024-06640-x","article-title":"EANM guidance document: Dosimetry for first-in-human studies and early phase clinical trials","volume":"51","author":"Stokke","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"4","key":"2024121023463368800_CIT0113","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s002590100490","article-title":"Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide","volume":"28","author":"Paganelli","year":"2001","journal-title":"Eur J Nucl Med."},{"key":"2024121023463368800_CIT0114","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/1748-717X-7-99","article-title":"Combination of peptide receptor radionuclide therapy with fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma","volume":"7","author":"Kreissl","year":"2012","journal-title":"Radiat Oncol."},{"issue":"8","key":"2024121023463368800_CIT0115","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1007\/s00259-012-2124-x","article-title":"PET SUV correlates with radionuclide uptake in peptide receptor therapy in meningioma","volume":"39","author":"H\u00e4nscheid","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2024121023463368800_CIT0116","first-page":"29","article-title":"Long-term results of multimodal peptide receptor radionuclide therapy and fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma","volume":"22","author":"Hartrampf","year":"2020","journal-title":"Clin Transl Radiat Oncol"},{"issue":"10","key":"2024121023463368800_CIT0117","doi-asserted-by":"crossref","first-page":"7089","DOI":"10.1007\/s00330-023-09697-8","article-title":"Semi-automated segmentation methods of SSTR PET for dosimetry prediction in refractory meningioma patients treated by SSTR-targeted peptide receptor radionuclide therapy","volume":"33","author":"Boursier","year":"2023","journal-title":"Eur Radiol."},{"issue":"6","key":"2024121023463368800_CIT0118","doi-asserted-by":"crossref","first-page":"946","DOI":"10.2967\/jnumed.122.265131","article-title":"Radioimmunoscintigraphy and pretreatment dosimetry of 131I-omburtamab for planning treatment of leptomeningeal disease","volume":"64","author":"Pandit-Taskar","year":"2023","journal-title":"J Nucl Med."},{"issue":"22","key":"2024121023463368800_CIT0119","doi-asserted-by":"crossref","first-page":"3644","DOI":"10.1200\/JCO.2005.05.4569","article-title":"Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma","volume":"24","author":"Mamelak","year":"2006","journal-title":"J Clin Oncol."},{"issue":"1","key":"2024121023463368800_CIT0120","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/bjc.1993.25","article-title":"Treatment of recurrent and cystic malignant gliomas by a single intracavity injection of 131I monoclonal antibody: Feasibility, pharmacokinetics and dosimetry","volume":"67","author":"Papanastassiou","year":"1993","journal-title":"Br J Cancer."},{"issue":"2","key":"2024121023463368800_CIT0121","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0167-8140(95)01514-H","article-title":"A pilot study of the treatment of patients with recurrent malignant gliomas with intratumoral yttrium-90 radioimmunoconjugates","volume":"34","author":"Hopkins","year":"1995","journal-title":"Radiother Oncol."},{"issue":"4","key":"2024121023463368800_CIT0122","first-page":"631","article-title":"Dosimetry of 131I-labeled 81C6 monoclonal antibody administered into surgically created resection cavities in patients with malignant brain tumors","volume":"40","author":"Akabani","year":"1999","journal-title":"J Nucl Med."},{"issue":"1","key":"2024121023463368800_CIT0123","first-page":"105","article-title":"Dosimetric model for locoregional treatments of brain tumors with 90Y-conjugates: Clinical application with 90Y-DOTATOC","volume":"47","author":"Ferrari","year":"2006","journal-title":"J Nucl Med."},{"issue":"2","key":"2024121023463368800_CIT0124","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/mp.14622","article-title":"Important pharmacokinetic parameters for individualization of 177 Lu-PSMA therapy: A global sensitivity analysis for a physiologically-based pharmacokinetic model","volume":"48","author":"Hardiansyah","year":"2021","journal-title":"Med Phys."},{"issue":"1","key":"2024121023463368800_CIT0125","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s40658-023-00565-4","article-title":"Predicting [177Lu]Lu-HA-DOTATATE kidney and tumor accumulation based on [68Ga]Ga-HA-DOTATATE diagnostic imaging using semi-physiological population pharmacokinetic modeling","volume":"10","author":"Siebinga","year":"2023","journal-title":"EJNMMI Phys"},{"issue":"4","key":"2024121023463368800_CIT0126","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1007\/s00259-020-05050-z","article-title":"IntraOmmaya compartmental radioimmunotherapy using 131I-omburtamab-pharmacokinetic modeling to optimize therapeutic index","volume":"48","author":"Yerrabelli","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"6","key":"2024121023463368800_CIT0127","first-page":"1042","article-title":"Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: A phase II study","volume":"46","author":"Akabani","year":"2005","journal-title":"J Nucl Med."},{"issue":"6","key":"2024121023463368800_CIT0128","first-page":"912","article-title":"Novel human IgG2b\/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: Phase I trial results","volume":"47","author":"Reardon","year":"2006","journal-title":"J Nucl Med."},{"issue":"9","key":"2024121023463368800_CIT0129","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1007\/s00259-006-0351-8","article-title":"Individual voxelwise dosimetry of targeted 90Y-labelled substance P radiotherapy for malignant gliomas","volume":"34","author":"Kneifel","year":"2007","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"6","key":"2024121023463368800_CIT0130","first-page":"477","article-title":"Receptor-mediated radionuclide therapy with 90Y-DOTA-D-Phe1-Tyr3-Octreotide: Preliminary report in cancer patients","volume":"14","author":"Paganelli","year":"1999","journal-title":"Cancer Biother Radiopharm."},{"issue":"8","key":"2024121023463368800_CIT0131","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1007\/s00259-015-3059-9","article-title":"A multicentre comparison of quantitative (90)Y PET\/CT for dosimetric purposes after radioembolization with resin microspheres: The QUEST Phantom Study","volume":"42","author":"Willowson","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"1","key":"2024121023463368800_CIT0132","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13550-017-0341-9","article-title":"Phantom validation of quantitative Y-90 PET\/CT-based dosimetry in liver radioembolization","volume":"7","author":"D\u2019Arienzo","year":"2017","journal-title":"EJNMMI Res"},{"issue":"6","key":"2024121023463368800_CIT0133","first-page":"963","article-title":"Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: Phase I trial results","volume":"2","author":"Brown","year":"1996","journal-title":"Clin Cancer Res."},{"issue":"3","key":"2024121023463368800_CIT0134","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2967\/jnumed.121.262069","article-title":"Dosimetric quantities in neuroendocrine tumors over treatment cycles with 177Lu-DOTATATE","volume":"63","author":"Roth","year":"2022","journal-title":"J Nucl Med."},{"issue":"5","key":"2024121023463368800_CIT0135","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/neuonc\/noad008","article-title":"EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection","volume":"25","author":"Capper","year":"2023","journal-title":"Neuro Oncol"},{"issue":"1","key":"2024121023463368800_CIT0136","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s42466-022-00184-x","article-title":"AMPLIFY-NEOVAC: A randomized, 3-arm multicenter phase I trial to assess safety, tolerability and immunogenicity of IDH1-vac combined with an immune checkpoint inhibitor targeting programmed death-ligand 1 in isocitrate dehydrogenase 1 mutant gliomas","volume":"4","author":"Bunse","year":"2022","journal-title":"Neurol Res Pract"},{"issue":"13","key":"2024121023463368800_CIT0137","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1007\/s00259-018-4044-x","article-title":"Correlation of dose with toxicity and tumour response to 90Y- and 177Lu-PRRT provides the basis for optimization through individualized treatment planning","volume":"45","author":"Cremonesi","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"12","key":"2024121023463368800_CIT0138","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1007\/s00259-021-05340-0","article-title":"To 1000 Gy and back again: A systematic review on dose-response evaluation in selective internal radiation therapy for primary and secondary liver cancer","volume":"48","author":"Roosen","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"2","key":"2024121023463368800_CIT0139","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1007\/s00259-021-05471-4","article-title":"Intra-therapeutic dosimetry of [177Lu]Lu-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer patients and correlation with treatment outcome","volume":"49","author":"Peters","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"5","key":"2024121023463368800_CIT0140","doi-asserted-by":"crossref","first-page":"753","DOI":"10.2967\/jnumed.123.266843","article-title":"SPECT\/CT image-derived absorbed dose to red marrow correlates with hematologic toxicity in patients treated with [177Lu]Lu-DOTATATE","volume":"65","author":"Blakkisrud","year":"2024","journal-title":"J Nucl Med."},{"issue":"6","key":"2024121023463368800_CIT0141","doi-asserted-by":"crossref","first-page":"923","DOI":"10.2967\/jnumed.123.267023","article-title":"Absorbed dose-response relationship in patients with gastroenteropancreatic neuroendocrine tumors treated with [177Lu]Lu-DOTATATE: One step closer to personalized medicine","volume":"65","author":"Hebert","year":"2024","journal-title":"J Nucl Med."},{"issue":"7","key":"2024121023463368800_CIT0142","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.2967\/jnumed.123.266991","article-title":"Relationship between absorbed dose and response in neuroendocrine tumors treated with [177Lu]Lu-DOTATATE","volume":"65","author":"Warfvinge","year":"2024","journal-title":"J Nucl Med."},{"key":"2024121023463368800_CIT0143","year":"2001"},{"key":"2024121023463368800_CIT0144"},{"key":"2024121023463368800_CIT0145"},{"key":"2024121023463368800_CIT0146","article-title":"Regulation (Eu) 2017\/745 of the European Parliament and of the Council","journal-title":"Off J Eur Union"},{"issue":"4","key":"2024121023463368800_CIT0147","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1007\/s00259-021-05538-2","article-title":"[68Ga]Ga-PSMA-11 PET imaging as a predictor for absorbed doses in organs at risk and small lesions in [177Lu]Lu-PSMA-617 treatment","volume":"49","author":"Peters","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"5","key":"2024121023463368800_CIT0148","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/RLU.0000000000004599","article-title":"177Lu-DOTATATE theranostics: Predicting renal dosimetry from pretherapy 68Ga-DOTATATE PET and clinical biomarkers","volume":"48","author":"Peterson","year":"2023","journal-title":"Clin Nucl Med."},{"key":"2024121023463368800_CIT0149","doi-asserted-by":"crossref","first-page":"103299","DOI":"10.1016\/j.ejmp.2024.103299","article-title":"A PBPK model for PRRT with [177Lu]Lu-DOTA-TATE: Comparison of model implementations in SAAM II and MATLAB\/SimBiology","volume":"119","author":"Vasi\u0107","year":"2024","journal-title":"Phys Med."},{"issue":"4","key":"2024121023463368800_CIT0150","doi-asserted-by":"crossref","first-page":"566","DOI":"10.2967\/jnumed.123.266268","article-title":"Single-time-point renal dosimetry using nonlinear mixed-effects modeling and population-based model selection in [177Lu]Lu-PSMA-617 therapy","volume":"65","author":"Hardiansyah","year":"2024","journal-title":"J Nucl Med."},{"issue":"4","key":"2024121023463368800_CIT0151","doi-asserted-by":"crossref","first-page":"566","DOI":"10.2967\/jnumed.123.266268","article-title":"Tumor lesion dosimetry of [177Lu]Lu-PSMA-617 therapy using single-time-point data, non-linear mixed-effects modeling and population-based model selection [abstract]","volume":"65","author":"Hardiansyah","year":"2024","journal-title":"J Nucl Med."},{"issue":"1","key":"2024121023463368800_CIT0152","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40658-017-0193-4","article-title":"Variations in the practice of molecular radiotherapy and implementation of dosimetry: Results from a European survey","volume":"4","author":"Sj\u00f6green Gleisner","year":"2017","journal-title":"EJNMMI Phys"},{"key":"2024121023463368800_CIT0153","doi-asserted-by":"crossref","first-page":"103196","DOI":"10.1016\/j.ejmp.2023.103196","article-title":"Implementation of dosimetry for molecular radiotherapy; results from a European survey","volume":"117","author":"Peters","year":"2024","journal-title":"Phys Med."},{"issue":"6","key":"2024121023463368800_CIT0154","first-page":"227","article-title":"Planning combined treatments of external beam radiation therapy and molecular radiotherapy","volume":"29","author":"Cremonesi","year":"2014","journal-title":"Cancer Biother Radiopharm."},{"issue":"11","key":"2024121023463368800_CIT0155","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.2967\/jnumed.123.265763","article-title":"Lesion dosimetry for [177Lu]Lu-PSMA-617 radiopharmaceutical therapy combined with stereotactic body radiotherapy in patients with oligometastatic castration-sensitive prostate cancer","volume":"64","author":"Grkovski","year":"2023","journal-title":"J Nucl Med."},{"issue":"11","key":"2024121023463368800_CIT0156","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.clon.2021.09.004","article-title":"Combining external beam radiation and radionuclide therapies: Rationale, radiobiology, results and roadblocks","volume":"33","author":"Abbott","year":"2021","journal-title":"Clin Oncol (R Coll Radiol)."},{"issue":"8","key":"2024121023463368800_CIT0157","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1007\/s00259-019-04334-3","article-title":"Call to arms: Need for radiobiology in molecular radionuclide therapy","volume":"46","author":"Terry","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"20","key":"2024121023463368800_CIT0158","doi-asserted-by":"crossref","first-page":"12369","DOI":"10.3390\/ijms232012369","article-title":"Understanding the radiobiological mechanisms induced by 177Lu-DOTATATE in comparison to external beam radiation therapy","volume":"23","author":"Delbart","year":"2022","journal-title":"Int J Mol Sci ."},{"issue":"11","key":"2024121023463368800_CIT0159","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.2967\/jnumed.123.265956","article-title":"European working group on the radiobiology of molecular radiotherapy. Second symposium of the european working group on the radiobiology of molecular radionuclide therapy","volume":"64","author":"Nonnekens","year":"2023","journal-title":"J Nucl Med."},{"issue":"4","key":"2024121023463368800_CIT0160","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/j.ijrobp.2010.08.022","article-title":"A treatment planning method for sequentially combining radiopharmaceutical therapy and external radiation therapy","volume":"80","author":"Hobbs","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"1","key":"2024121023463368800_CIT0161","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/14736691211060117","article-title":"ICRU REPORT 96, dosimetry-guided radiopharmaceutical therapy","volume":"21","author":"Sgouros","year":"2021","journal-title":"J ICRU."},{"issue":"2","key":"2024121023463368800_CIT0162","doi-asserted-by":"crossref","first-page":"216","DOI":"10.23736\/S1824-4785.16.02744-8","article-title":"Therapeutic schemes in 177Lu and 90Y-PRRT: Radiobiological considerations","volume":"61","author":"Sarnelli","year":"2017","journal-title":"Q J Nucl Med Mol Imaging."},{"issue":"11","key":"2024121023463368800_CIT0163","doi-asserted-by":"crossref","first-page":"4713","DOI":"10.1002\/mp.13820","article-title":"Personalized dosimetry is a must for appropriate molecular radiotherapy","volume":"46","author":"Stabin","year":"2019","journal-title":"Med Phys."}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noae200\/59469667\/noae200.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/26\/Supplement_9\/S242\/61000398\/noae200.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/26\/Supplement_9\/S242\/61000398\/noae200.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T18:47:26Z","timestamp":1733856446000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/26\/Supplement_9\/S242\/7798470"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,1]]},"references-count":163,"journal-issue":{"issue":"Supplement_9","published-online":{"date-parts":[[2024,10,1]]},"published-print":{"date-parts":[[2024,12,9]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noae200","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12]]},"published":{"date-parts":[[2024,10,1]]}}}